The Synergy CHC Corp. (NASDAQ: SNYR) SEC filings page brings together the company’s official disclosures as a smaller reporting company in the consumer health and wellness sector. Synergy develops and markets branded products such as FOCUSfactor® brain-health supplements and functional beverages and Flat Tummy® women’s wellness offerings, and its regulatory filings provide detailed insight into how this business is structured and financed.
Through annual reports on Form 10‑K and quarterly reports on Form 10‑Q, Synergy reports product sales, license revenue, gross profit, operating expenses, operating income, net income, and non‑GAAP measures like EBITDA and Adjusted EBITDA. These filings also describe working capital, inventory levels, debt obligations, and stockholders’ equity or deficit, giving investors a view of how the company funds expansion of its FOCUSfactor® and Flat Tummy® brands.
Current reports on Form 8‑K document material events such as quarterly earnings releases, public offerings of common stock, changes to equity incentive plans, authorization of preferred stock, and board or executive changes. For example, Synergy has used Form 8‑K to report an underwritten public offering of common stock, amendments to its 2024 Equity Incentive Plan, authorization of preferred stock, and governance updates including director appointments and role transitions.
Registration statements such as the Form S‑1 provide additional background on the company’s business, risk factors, use of proceeds, capital structure, and status as a smaller reporting company. Investors interested in ownership changes and executive incentives can review equity plan amendments and related disclosures within these filings. On this page, AI-powered tools can help summarize lengthy documents, highlight key financial and governance changes, and make complex sections of 10‑K, 10‑Q, 8‑K, and S‑1 filings easier to understand.
Use this filings hub to track Synergy CHC Corp.’s official financial reporting, capital raises, governance actions, and other regulatory disclosures that shape the outlook for SNYR stock.
Synergy CHC Corp. (SNYR) reports that Nasdaq has moved to delist its common stock following the company’s recent Chapter 11 filing. The company received a Delisting Notice on September 11, 2026, stating that trading on Nasdaq will be suspended at the opening of business on September 18, 2026.
Nasdaq’s decision cites the Chapter 11 bankruptcy cases, public interest concerns, questions about residual equity value for current holders, and the company’s ability to sustain compliance with Nasdaq listing standards. Synergy CHC Corp. does not intend to appeal, and a Form 25-NSE is expected to remove its securities from Nasdaq listing.
Synergy CHC Corp. (SNYR) has filed a voluntary petition for relief under chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Columbia, placing the company’s assets under the court’s jurisdiction and establishing it as a debtor-in-possession.
The company states it reasonably anticipates filing a plan of liquidation or reorganization within a forthcoming 120-day period, and a meeting of creditors will be scheduled under the Bankruptcy Code and related rules. Synergy CHC Corp. has engaged The VerStandig Law Firm, LLC as counsel and advisor in the case. In connection with the restructuring, Lauren P. Berret of Eisner Advisory Group LLC was engaged as chief restructuring officer, and on September 4, 2026, immediately after the chapter 11 filing, four directors—Alfred Baumeler, Nitin Kaushal, J. Paul SoRelle and Teresa Thompson—resigned from the Board, leaving Jack Ross as the sole remaining director. Baumeler also resigned as President effective August 31, 2026.
Synergy CHC Corp. (SNYR) reports that its term loan lenders have accelerated the company’s debt. On August 25, 2026, ACP Agency, LLC, acting as administrative and collateral agent under Synergy’s Term Loan Credit Agreement dated May 30, 2025, issued a Notice of Acceleration.
According to the notice, all commitments under the credit facility have been terminated and all obligations outstanding under the credit agreement and related loan documents have been accelerated and declared immediately due and payable. As of August 21, 2026, approximately $18.9 million was immediately due and payable, excluding additional interest, fees, costs and expenses, which continue to accrue. The acceleration follows Events of Default previously disclosed by the company.
Synergy CHC Corp. (SNYR) reported that Nasdaq has notified the company it is not in compliance with Nasdaq Listing Rule 5250(c)(1) because its Quarterly Report on Form 10‑Q for the quarter ended June 30, 2026 has not been filed with the SEC. The notice currently has no immediate effect on the listing or trading of Synergy’s common stock on Nasdaq.
Synergy has 60 days from the August 20, 2026 notice to submit a compliance plan to Nasdaq, which may, at its discretion, grant up to 180 days from the Q2 Form 10‑Q due date for Synergy to regain compliance. The company states it is unable to predict when, or whether, the Q2 Form 10‑Q will be filed or whether it will regain compliance.
Synergy CHC Corp. reported that on August 11, 2026 it received a notice of default from ACP Agency, LLC under its Term Loan Credit Agreement dated May 30, 2025. ACP asserted an Event of Default occurred after Synergy failed to make the interest payment due on August 3, 2026, following expiration of the cure period on August 6, 2026. ACP also stated that the forbearance period under a Forbearance Agreement dated May 28, 2026 terminated on August 6, 2026 and that a forbearance fee of $404,173.06 is now payable. Approximately $17.6 million principal remains outstanding under the Credit Agreement, excluding accrued interest, fees and expenses. ACP has reserved all rights and remedies, including charging interest at a post-default rate and accelerating the loan obligations.
Synergy CHC Corp. reports that on July 15, 2026, Costco Wholesale Corporation informed the company it will discontinue carrying Synergy’s FOCUSfactor products. Costco has been a significant customer for more than 16 years and accounted for approximately 58% of net revenue for the fiscal year ended December 31, 2025.
The company expects Costco’s decision to have a material adverse effect on its business, results of operations, liquidity and financial condition, and is evaluating available financing and other strategic alternatives in response.
Synergy CHC Corp. director and president Alfred Baumeler re-priced a stock option award covering 150,000 shares of common stock. On this Form 4, a prior option for 150,000 shares with a $2.38 per share exercise price was canceled and a new option for 150,000 shares with a $0.21 per share exercise price was granted in its place.
According to the footnotes, this reduction in exercise price is treated under Section 16 as a cancellation and re-grant of the same award. The new option vests on the same schedule as the original option, with one-third vesting on the first anniversary of September 18, 2025 and the remaining two-thirds vesting in equal monthly installments over the following 24 months, subject to continued service. The new option expires on the five-year anniversary of the original grant date. These are compensation-related derivative transactions, with no reported open-market purchases or sales of common shares.
Synergy CHC Corp. Chief Financial Officer Jaime Fickett reported a restructuring of an existing stock option award. An original option covering 150,000 shares of common stock with a $2.38 exercise price was deemed canceled for Section 16 purposes, and a new option for 150,000 shares was granted with a reduced exercise price of $0.21 per share.
According to the footnotes, this reduction in exercise price is treated as a material modification, with the new option keeping the same vesting schedule and a five-year term from the original September 18, 2025 grant date. One-third of the option vests on the first anniversary of that date, and the remaining two-thirds vest in equal monthly installments over the following 24 months, subject to continued service.
Synergy CHC Corp. insider activity shows an option repricing for shares held indirectly through Kenek Brands Inc., which is controlled by CEO and Chairman Ross Jack. A stock option for 750,000 shares of common stock with a $2.38 exercise price was deemed canceled and disposed of back to the company.
On the same date, Kenek Brands Inc. received a new stock option covering 750,000 underlying shares at a reduced exercise price of $0.21 per share. The new option keeps the original vesting schedule tied to the September 18, 2025 grant date and expires on the five-year anniversary of that date. The filing notes Jack’s indirect beneficial ownership through Kenek Brands Inc., with beneficial ownership disclaimed except for his pecuniary interest.
Synergy CHC Corp. reported the results of its 2026 annual stockholder meeting. Stockholders approved amending the 2024 Equity Incentive Plan to increase the pool to 150,000,000 common shares and allow repricing of outstanding awards. They also authorized the board to implement one or more reverse stock splits with an aggregate ratio up to 1‑for‑200.
Investors ratified RBSM LLP as auditor for the 2026 fiscal year, approved the full issuance of shares underlying a Lender Warrant under Nasdaq rules, and elected five directors to serve until the 2027 annual meeting. On the April 24, 2026 record date, 14,899,883 common shares were outstanding, with about 65% of votes represented at the meeting.